Abstract
Disruption in the endocannabinoid system in FXS is associated with social anxiety and irritability. Cannabidiol (CBD) acts as a negative allosteric modulator at presynaptic CB1 receptors, a 5HT1A agonist and a D2 partial agonist. FXS causes intellectual disability, making symptom recognition and self-report problematic. Therapeutic response must rely on objective description of change. ZYN002 is pharmaceutically manufactured transdermal CBD.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call